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Gender and 30-day outcome in patients undergoing
endovascular aneurysm repair (EVAR): An analysis
using the ACS NSQIP dataset
Nick N. Abedi, MD, Daniel L. Davenport, PhD, Eleftherios Xenos, MD, PhD, Ehab Sorial, MD,
David J. Minion, MD, and Eric D. Endean, MD, Lexington, Ky
Purpose: Prior studies have demonstrated higher in-hospital mortality in women undergoing open abdominal aortic
aneurysm repair. The current study evaluates the relationship between gender and 30-day outcomes for endovascular
aneurysm repair (EVAR) in a multicenter, contemporary patient population.
Methods: Patients in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP)
participant use file that underwent EVAR of abdominal aortic aneurysm (AAA) from 2005 to 2007 were identified by
CPT codes. Outcomes analyzed were 30-day mortality, morbidity (one or more of 21 complications defined by the ACS
NSQIP protocol), length of hospital stay, and six complication subgroups. Preoperative risk factors, intraoperative
variables, and outcomes were compared across genders using 2 (binary and categorical variables) and t tests (continuous
variables). The relationship of gender to outcomes was further evaluated using multivariate logistic regressions to adjust
for pre- and intraoperative risk variables.
Results: In 3662 EVAR patients, 647 (17.7%) were women and 3015 (82.3%) men with mean ages of 75.1  9.0 and
73.7  8.5 years (P < .001). Tube graft (360, 9.8%); bifurcated, one docking limb (1624, 44.3%); bifurcated, two
docking limbs (1294, 35.3%); unibody (218, 5.9%); and aorto-uni-iliac/femoral (166, 4.4%) repairs were performed.
Tube and aorto-uni-iliac/femoral grafts were more common in women (21.4% vs 12.8%, P < .001) than men, as were
femoral/femoral crossovers (3.9% vs 1.8%, P  .011) and iliac or brachial exposures (2.8% vs 1.0%, P  .009). Overall
morbidity and mortality were 11.9% and 2.1%, respectively. Mortality in women was significantly higher (3.4% vs 2.1%,
P  .014), as was morbidity (17.8% vs 10.6%, P < .001). Of thirteen independent preoperative risk factors for mortality
or morbidity, women had a higher incidence in five: emergent operation, functional dependence, recent weight loss,
underweight status or morbid obesity, and severe chronic obstructive pulmonary disease (COPD). After adjustment for
these variables, the odds ratio (OR) formortality in women vsmenwas 1.52 (95% confidence interval [CI] 0.85-2.69, P
.157); OR for morbidity was 1.65 (95% CI 1.28-2.14, P< .001). Female gender was also found to be an independent risk
factor for length of stay (Beta 0.7 days, 95%CI 0.2-1.2, P .006), infectious complications (OR 1.49, 95%CI 1.10-2.03,
P  .011), wound complications (OR 1.80, 95% CI 1.12-2.90, P  .015) and postoperative transfusion (OR 2.92, 95%
CI 1.39-6.13, P  .002).
Conclusions:Mortality and morbidity were higher in women than men undergoing EVAR. Multivariate analysis showed
that the increased risk of mortality was related to women presenting more emergently, more debilitated (recent weight
loss and functional dependence), and requiring iliac or brachial exposure. After adjustment for multiple preoperative and
operative factors, women remained at significantly higher risk for the development of a broad range of complications and
increased length of stay. ( J Vasc Surg 2009;50:486-91.)Abdominal aortic aneurysms (AAA) account for 45,000
deaths per year in the United States with a 4:1 male to
female predominance.1 Despite having a less frequent prev-
alence, it has been suggested that women with AAA have a
higher risk of rupture and significantly higher mortality and
morbidity rates for both elective and emergent repair.2,3
With the introduction of endovascular devices, endovascu-
lar aneurysm repair (EVAR) has rapidly increased over the
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486past several years. Multiple reports such as the UK EVAR
and Dutch Randomized Endovascular Aneurysm Manage-
ment (DREAM) trials have demonstrated decreased 30-
day mortality with the use of endovascular repair compared
with open repair.4,5
While several authors have included the influence of
gender on outcomes following endovascular repair of AAA,
the current literature suffers from inherent deficiencies.
Because AAA is a disease primarily affecting men, studies to
date often include a relatively small sample size of women.
This is especially problematic with reports that come from a
single institution. Reports of industry sponsored trials that
are designed to demonstrate the efficacy of an endograft
may have selection bias related to industry protocols; spe-
cifically exclusion criteria that may make it more difficult to
enroll women due to difficult anatomic conditions. One
difference related to gender often noted in these studies
appears to be higher rates of access related complications
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studies focused on comparisons between open and endo-
vascular aneurysm repair and differences in outcome asso-
ciated with gender were secondary observations.
The purpose of the current study was to test the hy-
pothesis that gender influences 30-day outcomes for endo-
vascular aneurysm repair. The American College of Sur-
geons National Surgical Quality Improvement Program
(ACS NSQIP) database was used to identify a large patient
population undergoing EVAR from multiple and diverse
medical centers in order to evaluate contemporary out-
comes.
METHODS
Data from the ACS NSQIP participant use file contain-
ing surgical cases submitted by 173 hospitals throughout
theUnited States were analyzed for the calendar years 2005
to 2007. Dedicated nurse clinical reviewers at each hospital
prospectively enrolled patients and collected data in a stan-
dardized fashion according to strict ACS NSQIP defini-
tions. The systematic sample was obtained by taking the
first 40 cases per nurse reviewer on an 8-day cycle from the
operating room log, ensuring that no particular operating
room day block time would bias the weighting of cases.
Nurse reviewers received training regarding definitions and
data extraction, had continuing education and monitoring
through the ACS-NSQIP program, and were assessed for
inter-rater reliability during biennial site visits. Information
was obtained from computerized and/or paper patient
medical records, physician office records, and telephone
interviews with patients. Patients are followed after hospital
discharge up to 30 days postoperatively. The accuracy and
reproducibility of the data have been previously demon-
strated.8
The database was queried for patients undergoing
EVAR as identified by the primary procedure CPT codes
for aortic tube prosthesis (CPT 34800), modular bifur-
cated prosthesis - one docking limb (CPT 34802), modular
bifurcated prosthesis - two docking limbs (CPT 34803),
unibody bifurcated prosthesis (CPT 34804), and aorto-
uniiliac or unifemoral prosthesis (CPT 34805). Patients
were further classified as to whether they had had an iliac or
brachial exposure (CPT 34820, 34833 or 34834), second-
ary femoral-femoral crossover (CPT 34813), coil embolism
(CPT 37204), and/or single or multiple extension cuff(s)
(CPT 34825 or 37204) during EVAR.
Data were analyzed on 55-patient preoperative risk
factors, eight procedure and intraoperative variables, and
30-day outcomes. The outcomes examined were mortality,
any morbidity as defined by the occurrence of one or more
of 21 postoperative adverse events uniformly defined by the
ACS NSQIP, and length of hospital stay. Adverse events
were further classified into subgroups including infectious,
wound, pulmonary, renal, transfusion, and graft failure.
According to the ACS NSQIP manual, graft failure was
defined as, “mechanical failure of an extra-cardiac graft orprosthesis . . . requiring return to the operating room,
interventional radiology, or a balloon angioplasty.” Infec-
tious complications included superficial, deep, or organ/
space surgical site infection, pneumonia, sepsis, septic
shock, and/or urinary tract infection. Wound complica-
tions included superficial, deep, or organ/space surgical
site infection and/or wound dehiscence. Pulmonary com-
plications included pneumonia, unplanned intubation
and/or ventilation 48 hours postoperatively. Postopera-
tive transfusion was recorded as an adverse event if the
patient received 4 units of packed red blood cells within
72 hours of surgery.
Statistical analysis. Patients were grouped by gender
and bivariate differences in preoperative risk factors,
procedure variables, and outcomes were analyzed using
2 (binary or categorical variables) and t tests (continu-
ous variables). The relationship of gender with mortality,
morbidity, and each of the six complication subgroups
was further evaluated using multivariate logistic regres-
sions to adjust for risk and procedure variables. For each
model, all ACS NSQIP preoperative risk variables were
considered, but only those independently predictive of
the outcome were included in a forward stepwise fashion
(P  .05 for entry, P  .10 for exit). Procedure variables
were then added in a similar forward stepwise manner
and lastly gender was forced into the final model. Cali-
bration of the logistic regression models was calculated
using the c-index and Hosmer-Lemeshow (H-L) statis-
tic. Length of stay was similarly analyzed using multivar-
iate linear regression.
RESULTS
From the database, 3662 patients were identified who
underwent EVAR including: tube grafts (360, 9.8%); bifur-
cated, one docking limb (1624, 44.3%); bifurcated, two
docking limbs (1294, 35.3%); unibody (218, 5.9%); and
aorto-uni-iliac/femoral (166, 4.4%) repair. The use of tube
grafts and aorto-uni iliac/femoral repairs was associated
with a higher percentage of emergent operations, greater
30-day morbidity and mortality, and longer hospital stays
(Table I, all 2or analysis of variance [ANOVA] P .001).
EVAR patients included 647 (17.7%) women and 3015
(82.3%) men with mean ages of 75.1  9.0 years and
73.7  8.5 years respectively (P  .001). Numerous gen-
der differences in preoperative risk variables were identified.
(See Appendix, Table AI, online only, for complete list of
ACS NSQIP risk variables and occurrence rates by gender.)
Risk variables that were found by forward stepwise regres-
sion analysis to be predictive of EVARmortality or morbid-
ity are shown in Table II with occurrence rates by gender.
Of these, women were more likely to undergo emergent
surgery, be functionally dependent, have recent weight
loss, be underweight or morbidly obese, and/or have se-
vere chronic obstructive pulmonary disease. Men were
more likely to have elevated creatinine levels. Intraopera-
tively, women were more likely to have EVAR using a tube
or aorto-uni-iliac/femoral graft that demonstrated higher
by typ
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iliac or brachial exposures, more femoral-femoral cross-
overs, more frequent blood transfusion, and significantly
Table I. Patient count by type EVAR
Type of repair CPT code
No of patien
(% of total)
Aortic
Tube graft 34800 360 (9.8)
One docking limb 34802 1624 (44.3
Bifurcated, two docking limbs 34803 1294 (35.3
Unibody 34804 218 (5.9)
Aorto-uni-iliac/femoral 34805 166 (4.5)
Total 3662
EVAR, Endovascular aneurysm repair.
Emergent status, morbidity, mortality, and hospital stay varied significantly
Table II. EVAR preoperative patient characteristics by
gender
Characteristic Women Men
P
value
No. of patients 647 (17.7%) 3015 (82.3%)
Age (mean years  SD) 75.1  9.0 73.7  8.5 .001*
Emergent procedure 6.5% 4.3% .020*
ASA physical status class 4
or 5 22.3% 20.1% .225
Preoperative systemic
infection .556
SIRS 3.1% 2.2%
Sepsis .3% .2%
Septic shock .3% .4%
Functional dependence .001*
Partial 6.5% 4.0%
Full 2.6% 1.3%
On dialysis 1.9% 1.2% .180
Recent weight loss 10% 3.2% 1.8% .015*
Disseminated cancer .8% .9% .761
Medically treated
hypertension 80.7% 77.9% .125
Blood urea nitrogen 40
mg/dL 4.5% 3.7% .380
Serum creatinine 1.2
mg/dL 21.8% 34.2% .001*
Body mass index obesity
class .001*
Underweight
(BMI  18.5) 5.3% 2.0%
Morbidly obese
(BMI  40) 3.0% 2.2%
Medically treated diabetes .058
Oral 9.4% 11.9%
Insulin 1.7% 2.7%
History of severe COPD 23.3% 18.2% .003*
SIRS, Systemic inflammatory response syndrome; COPD, chronic obstruc-
tive pulmonary disease; ASA, American Society of Anesthesiologists; BMI,
body mass index; EVAR, endovascular aneurysm repair.
Characteristics shown are independent predictors of either mortality or
morbidity in EVAR patients (except age).
P value is for 2 (categorical and binary variables) or t test (age) of gender
differences. N  3662.
*Highlights P values 0.05.longer operative times (Table III).Overall 30-day mortality was 2.1% and was higher in
women (3.4% vs 2.1%; P  .014, Table IV). Eight inde-
pendent preoperative risk factors for mortality were identi-
fied bymultivariate regression. They were by order of entry:
(1) ASA class, (2) systemic infection, (3) emergent surgery,
(4) recent weight loss, (5) currently on dialysis, (6) dissem-
inated cancer, (7) functional dependence, and (8) medi-
cally treated hypertension. (Rates by gender are reported in
Table II, independent odds ratios are reported in the
Appendix, Table AII, online only.) Use of iliac or brachial
exposure was a significant operative risk variable. After
adjustment for these variables, the odds ratio for mortality
in women vs men was 1.52 (95% CI 0.85-2.69, P .157).
The c-index for the mortality model was 0.85 and the H-L
Emergent
%
30-day
morbidity %
30-day
mortality %
Hospital stay
(days  SD)
11.1 18.1 5.0 5.7  8.5
3.9 10.0 1.8 3.5  6.4
3.2 11.2 1.3 3.7  6.1
2.8 10.1 1.8 3.5  5.7
12.7 24.7 6.0 6.1  8.0
4.7 11.9 2.1 3.9  6.6
e of EVAR (2 or ANOVA P  .001, N  3662).
Table III. Intraoperative characteristics by gender
Procedure/intraoperative
variable Women Men
P
value
No. of patients 647 (17.7%) 3015 (82.3%)
Type of graft/procedure .001*
Tube graft 14.1% 8.9%
Bifurcated, one docking
limb 43.6% 44.5%
Bifurcated, two docking
limbs 30.3% 36.4%
Unibody 4.8% 6.2%
Aorto-uni-iliac/femoral 7.3% 3.9%
Adjunct procedure(s)
Iliac or brachial
exposure 2.8% 1.0% .009*
Femoral-femoral
crossover 3.9% 1.8% .011*
One or more extension
cuffs 25.7% 28.5% .137
Coil embolism 2.2% 3.2% .132
Operative duration
(minutes  SD) 182  88.6 162  73.7 .001*
Transfused
intraoperatively 25.3% 12.7% .001*
Packed red blood cells
(mean units  SD of
those transfused) 3.3  3.3 3.1  3.6 .516
P value is for 2 (categorical and binary variables) or t test (continuous
variables) of differences across gender. N  3662.
*Highlights P values 0.05.ts
)
)statistic P value was .315.
iac gr
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(17.8% vs 10.6%; P  .001, Table IV). Likewise, the
incidence of adverse events in each of the six complication
subgroups as well as length of stay was significantly higher
in women (P  .001, Table III). Eight independent pre-
operative predictors of morbidity were by order of entry:
(1) emergent surgery, (2) functional dependence, (3) sys-
temic infection, (4) elevated blood urea nitrogen, (5) ele-
vated serum creatinine, (6) body mass index obesity class,
(7) medically treated diabetes, and (8) severe chronic ob-
structive pulmonary disease [COPD]. (Rates by gender are
reported in Table II, independent odds ratios are reported
in the Appendix, Table AII, online only) As mentioned for
mortality, women had significantly higher incidence of
emergent surgery and functional dependence. They also
were more frequently underweight or morbidly obese.
Elevated serum creatinine was higher in men. Independent
procedure variables predictive of morbidity were primary
repair type, iliac or brachial exposure, and femoral-femoral
crossover: women had significantly greater risk in all three.
After adjustment for these preoperative and procedure risk
variables, the odds ratio for morbidity in women was 1.65
(95% CI 1.28-2.14, P  .001). After similar adjustment,
female gender remained significantly predictive of length of
hospital stay (Beta 0.7d, 95% CI 0.2-1.2d, P  .008),
infectious complications (O.R. 1.49, 95% CI 1.10-2.03,
P  .011), wound occurrences (O.R. 1.80, 95% CI 1.12-
2.90, P .015), and postoperative transfusion (O.R. 2.92,
95% CI 1.39-6.13, P  .005) (Table IV). The specific
adjustment variables for the complication subgroup multi-
variate logistic regressionmodels are listed in the Appendix.
The model c-indices ranged from 0.64 for graft failure to
0.85 for postoperative transfusion and all H-L statistic
Table IV. Outcomes by gender: unadjusted and adjusted
p-value is for 2 test except for t test of hospital stay
30-day outcome
All
N  3662
Female
N  647 N
Mortality 2.1% 3.4%
Overall morbidityc 11.9% 17.8%
Length of hospital stay,
mean days  SD 3.9  6.6 5.1  6.7 3.
Infectious complicationd 7.3% 11.1%
Wound occurrencee 2.5% 4.3%
Pulmonary complicationf 4.4% 6.5%
Renal insufficiency or failure 2.3% 2.8%
Postop transfusion 4 u.
w/in 72 h of procedure 1.0% 2.3%
Graft/prosthesis failureg 1.4% 2.3%
Bivariate P value is for 2 test except for t test of hospital stay.
aOutcome model Hosmer-Lemeshow statistic P values, c indices, and indep
bMultivariate result for length of hospital stay is the linear regression beta c
cComposite morbidity was one or more of 21 adverse events uniformly defi
dInfectious complications included deep, superficial, or organ/space surgica
eWound occurrence included deep, superficial, or organ/space surgical site
fPulmonary complication included ventilation  48 h, unplanned intubatio
gGraft/prosthesis failure was defined as, “mechanical failure of an extracard
radiology, or a balloon angioplasty.”P values were greater than .05.DISCUSSION
The current study, in a large contemporary, multi-
center population demonstrates that the 30-day mortality
and morbidity in patients undergoing EVAR is higher in
women than men. Multivariate analysis indicated that the
increased risk of mortality could be accounted for by more
emergent operations, physical debilitation (recent weight
loss and functional dependence), and greater need for iliac
or brachial exposure in women. From the data set, we
cannot determine how many emergent operations were
related to ruptured AAA, but it is well known that AAA
repair done under emergent conditions is associated with a
higher mortality.9 It may be that AAA in women, being
more common in men, is not diagnosed until symptomatic,
resulting in the need for more frequent emergent interven-
tion. Concerning dependent functional status, the 2007
ACS NSQIP national risk modeling placed functional sta-
tus the first of 31 independent predictors of 30-day mor-
tality in vascular surgery patients10, but it remains unclear
why women undergoing EVAR have a higher incidence.
As opposed to mortality, multivariate analysis demon-
strated that gender was independently associated with a
higher risk for development of one or more postoperative
complications after adjustment for available ACS NSQIP
risk and operative factors. Specifically, women had indepen-
dent increased risk for infectious complications, wound
occurrences, and need for transfusion as well as longer
length of stay. In addition to the mortality risk factors
mentioned above, women had higher incidence of morbid
obesity and severe COPD, independent predictors of over-
all morbidity. Again, we are unable to determine why
women treated with EVAR had higher incidence of these
ignificant risk factors and procedure variables. Bivariate
15
Bivariate
P value
Multivariatea odds ratio
Female vs male (95% CI)
Multivariate
P value
.014 1.52 (0.85-2.69) .157
.001 1.65 (1.28-2.14) .001
.6 .001 0.7b (0.2-1.2) .008
.001 1.49 (1.10-2.03) .011
.001 1.80 (1.12-2.90) .015
.001 1.41 (0.93-2.13) .106
.001 1.33 (0.74-2.38) .344
.001 2.92 (1.39-6.13) .005
.001 1.72 (0.92-3.22) .088
t predictors are listed in appendix Table A1.
ent in days.
y the ACS NSQIP.
nfection, pneumonia, sepsis or septic shock, and/or urinary tract infection.
ion, and/or wound dehiscence.
/or pneumonia.
aft or prosthesis . . . requiring return to the operating room, interventionalfor s
Male
 30
1.9%
10.6%
7  6
6.5%
2.2%
4.0%
2.2%
0.7%
1.2%
enden
oeffici
ned b
l site i
infect
n, andrisk factors.
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and iliac exposure, femoral-femoral cross over graft, and
type of EVAR procedure) were associated with higher
morbidity and mortality. We hypothesize that women have
more challenging anatomy, factors not available in the ACS
NSQIP data set. Such factors could include neck angula-
tion, size of the neck, small iliac diameter, associated occlu-
sive disease, and tortuosity of the iliac arteries; and condi-
tions that would affect the procedure. Challenging vascular
anatomy could also contribute to longer operative duration
and increased need for transfusion as observed in women
observed in this study. Buth et al reported that the female
gender and a patient age greater than 75 were significant
risk factors for the incidence of endoleak and suggested that
increased age may be associated with more complex aortic
anatomy.11 Others have commented on the fact that
women tend to have smaller vessels and a higher need for
adjunct procedures to gain access for EVAR deploy-
ment.12,13
These findings lead to questions that should be ad-
dressed in future studies. It would be important to include
anatomic details such as size of the aneurysm, details con-
cerning the aortic neck, and specifics regarding the access
vessels in men compared with women. This information
would help determine if the difficult aortic anatomy in
women is related to choice of operation, length of proce-
dure, and transfusion requirement. It would also be critical
to evaluate why women have a higher incidence of emer-
gent EVAR and why women are more likely to present
more physically debilitated than men. Such information
could impact AAA surveillance protocols, especially as they
relate to women. Since the ACS NSQIP database provides
only 30-day follow-up, long-term outcome and durability
cannot be determined. It would be important to determine
if early outcomes parallel long-term results. Since the data
used in the study was pooled frommany institutions, future
studies might also focus on the volume of individual insti-
tutions and/or surgeons and the contribution of patients
from private or academic institutions.
There are significant benefits of the current study. This
study demonstrates outcomes for EVAR prospectively and
systematically sampled from a broad range of academic and
private hospitals. As such, the data represents an accurate
picture of current 30-day outcomes for patients treated
with endografts in the United States. The ratio of women
to men (1:4.66) and overall mortality rate in our study
(2.1%) compares favorably with those reported by others.11
The robust clinical risk variables, as tabulated in the ACS
NSQIP data set, provides novel observations regarding the
physical and emergent status of women presenting for
EVAR as well as operative differences.
In summary, we have demonstrated that women un-
dergoing EVAR have an increasedmortality andmorbidity.
The mortality risk in women is associated with emergent
status, physical condition, and procedure variables. Despite
adjustment for multiple preoperative and operative factors,
women remained at significantly higher risk for the devel-opment of a broad range of complications. While the
reasons for this risk cannot be definitively identified from
data obtained in the current study, we hypothesize that at
least one factor contributing to this finding may be more
challenging aortic anatomy in women. Until further studies
identify why women present more emergently and in a
more debilitated state, appropriate patient selection, man-
agement of comorbid conditions, and attention to ana-
tomic factors that make EVAR more difficult may result in
improved outcomes for women undergoing EVAR.
The American College of Surgeons National Surgical
Quality Improvement Program and the hospitals partici-
pating in the ACS NSQIP are the source of the data used
herein; they have not verified and are not responsible for
the statistical validity of the data analysis or the conclusions
derived by the authors.
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Table AI, online only. Prevalence of ACS NSQIP risk factors by gender
Risk factor
Female
n  647
Male
n  3015 P value
Age in years with patients over 89 coded as 90 (mean  SD) 75.1  9.0 73.7  8.5 .001
Race .004
Native American .3% .1%
Asian .8% 1.3%
African American 6.5% 3.4%
Hispanic 2.0% 1.8%
Unknown 8.5% 8.9%
White 81.9% 84.6%
Emergency case 6.5% 4.3% .020
ASA physical status classification .460
1 .3% .1%
2 7.6% 7.2%
3 69.8% 72.6%
4 21.2% 19.1%
5 1.1% 1.0%
Pack-years of smoking 35.14 42.71 .001
Current smoker within one year 35.4% 28.1% .001
EtOH  2 drinks/day in 2 wks before admission 1.1% 4.6% .001
Do not resuscitate (DNR) status 1.1% .4% .018
Ventilator dependent 1.4% .3% .001
History of severe COPD 23.3% 18.2% .003
Current pneumonia .9% .3% .013
Ascites .5% .4% .812
Esophageal varices .0% .1% .512
Hypertension requiring medication 80.7% 77.9% .125
Hx of CHF, angina, or AMI 4.3% 5.0% .466
Prior cardiac operation or PCI 27.4% 41.2% .001
History of revasc./amput. forperiph. vascular disease 7.1% 6.1% .355
Rest pain/gangrene 1.5% 0.9% .160
Acute renal failure .3% .4% .659
Currently on dialysis 1.9% 1.2% .180
History of stroke/CVA/TIA/hemiplegia 15.0% 15.2% .882
Impaired sensorium 1.1% .6% .138
Coma  24 hours .3% .1% .190
Tumor involving central nervous system .0% .1% .422
Open wound/wound infection 2.3% 1.1% .017
Steroid use for chronic condition 5.6% 4.3% .153
Loss of  10% body weight in last 6 months 3.2% 1.8% .015
Disseminated cancer .8% .9% .761
Chemotherapy for malignancy in  30 days preop .3% .3% .847
Radiotherapy for malignancy in last 90 days .5% .4% .909
Bleeding disorder 1.7% 11.2% .706
Transfusion  4 units PRBCs in 72 hours before surgery .6% .1% .016
Serum albumin g/dL, mean  SD 3.79  0.66 3.87  0.55 .023
International normalized ratio of prothrombin time, mean  SD 1.12  0.34 1.11  0.33 .612
Alkaline phosphatase  125 U/L 5.4% 4.0% .120
Sodium  135 mmol/L 9.0% 5.8% .003
Sodium  145 mmol/L .8% 1.5% .152
BUN  40 mg/dL 4.5% 3.7% .380
Creatinine  1.2 mg/dL 21.8% 34.2% .001
Bilirubin  1.0 mg/dL 3.2% 5.7% .011
Serum glutamic oxaloacetic transaminase  40 U/L 3.4% 3.1% .676
White blood cell count  4500/cumm 5.6% 4.4% .205
White blood cell count  11000/cumm 5.9% 6.6% .495
Hematocrit  38% 44.7% 25.9% .001
Hematocrit  45% 6.3% 16.5% .001
Platelet count  150,000/cumm 8.5% 13.1% .001
Platelet count  400,000/cumm 4.0% 2.3% .014
Partial thromboplastin time  35 s 7.9% 8.3% .711
Prothrombin time  13.2 s 3.3% 32.8% .216
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Risk factor
Female
n  647
Male
n  3015 P value
Body mass index (BMI) obesity category kg/m2 .001
18.5 5.3% 2.0%
18.5  BMI  25 36.7% 26.4%
25  BMI  30 32.3% 40.5%
30  BMI  35 16.3% 21.9%
35  BMI  40 6.4% 7.0%
 40 3.0% 2.2%
Medically treated diabetes .058
None 88.9% 85.4%
Orally treated 9.4% 11.9%
Insulin treated 1.7% 2.7%
Dyspnea .010
None 72.5% 76.2%
After mild exertion 23.6% 21.8%
At rest 3.9% 2.1%
Functional dependence .001
None 90.9% 94.6%
Partial 6.5% 4.0%
Full 2.6% 1.3%
Preoperative systemic infection .556
None 96.3% 97.2%
SIRS 3.1% 2.2%
Sepsis .3% .2%
Septic shock .3% .4%
P value is for 2 (categorical and binary variables) or t test (continuous variables) of differences across gender. N  3662.
AMI, Acute myocardial infarction; ASA, American Society of Anesthesiologists; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease;
CHF, congestive heart failure; CVA, cerebral vascular accident; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
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aortic aneurysm patients: model H-L statistic P values, c indices, and independent risk variable odds ratios from forward
stepwise regression (P for entry  .05, for exit  0.10), N  3660
Model (% occurrence)
Mortality
(2.1%)
Composite
morbiditya
(11.9%)
Infectious
complic.b
(7.3%)
Wound
occurrencec
(2.5%)
Pulmonary
complic.d
(4.4%)
Renal
insufficiency
or failure
(2.3%)
Postop
transfusion 4u.
w/in 72 h
of procedure
(1.0%)
Graft/
prosthesis
failuree
(1.4%)
Hosmer-Lemeshow
Statistic P value
.315 .161 .529 .131 .889 .635 .724 .931
C index 0.85 0.70 0.69 0.72 0.81 0.83 0.85 0.64
Independent procedure and risk variable odds ratios in each model; * P  .10 in final model; “—” indicates variable was not in model.
Female vs male 1.52 1.65* 1.49* 1.80* 1.41 1.33 2.92* 1.72*
Iliac or brachial exposure 3.39* 1.85* — — 3.31* — — —
Femoral/femoral
crossover — 1.85* 2.19* 4.29* 2.62* 2.09* — —
Primary CPT vs 34800
34802 — 0.65* — — 0.40* 0.54* 0.34* —
34803 — 0.79 — — 0.55* 0.52* 0.25* —
34804 — 0.65 — — 0.67 0.40 0.24 —
34805 — 1.10 — — 0.63 0.93 0.55 —
Coil embolism — — — — 2.94* — — —
Preop systemic inf. vs
none
SIRS 2.04* 3.49* 3.39* — 3.41* 3.15* 3.31* —
Sepsis 8.58* 4.91* 5.86* — 3.03 0.40 9.00* —
Septic Shock 9.10* 0.93 1.16 — 0.64 2.81 0.00 —
ASA Class vs 1-3
ASA 4 2.87* — — — 1.94* — — —
ASA 5 8.80* — — — 2.43* — — —
Emergent surgery 4.24* 3.07* 2.81* — 4.26* 4.50* 3.08* —
On dialysis 4.53* — 3.29* 5.26* — 0.12* — —
Recent weight loss  10% 3.56* — — — — — 3.40* —
Disseminated cancer 4.77* — — — — — — —
Functional status vs
independent
Partially dependent 1.27 1.79* 2.04* — 1.53 1.67 2.45* —
Fully dependent 3.61* 3.41* 2.68* 3.02* 2.15* 6.96* —
Treated hypertension 2.41* — — 0.57* — — — —
BUN  40 — 1.71* — — — 2.98* — —
Creatinine  1.2 — 1.51* — — 1.66* 2.18* — —
BMI vs 18.5-25
BMI  18.5 — 1.72* 2.52* 1.04 3.37* — — 2.71*
25  BMI  30 — 0.86 1.11 1.17 0.95 — — 0.68
30  BMI  35 — 1.03 1.47* 2.44* 0.89 — — 0.45*
35  BMI  40 — 1.02 1.26 2.10 1.50 — — 0.46
BMI  40 — 2.14* 4.26* 8.99* 1.14 — — 0.64
Diabetes vs none
Orally treated — 1.35* — — — — — —
Insulin treated — 1.83* — — — — — —
COPD — 1.31* — — — — 2.28* —
Esophageal varices — — 21.14* — 32.59* — — —
Hematocrit  38% — — 1.33* 1.76* — — — —
CNS tumor — — 11.21* — — — — —
Bleeding disorder — — — 1.94* — — — —
Smoker — — — 1.64* — — 0.13* —
DNR status — — — — 4.94* — — —
Sodium  135 — — — — 0.42* — — —
Serum albumin — — — — — 0.42* — —
On steroids for chronic
condition — — — — — 3.27* — —
AlkPhos  125 0.09* — —
Preop renal failure 4.04* — —
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Model (% occurrence)
Mortality
(2.1%)
Composite
morbiditya
(11.9%)
Infectious
complic.b
(7.3%)
Wound
occurrencec
(2.5%)
Pulmonary
complic.d
(4.4%)
Renal
insufficiency
or failure
(2.3%)
Postop
transfusion 4u.
w/in 72 h
of procedure
(1.0%)
Graft/
prosthesis
failuree
(1.4%)
Recent radiotherapy — — — — — — 8.16* —
Rest pain/gangrene — — — — — — — 6.41*
Each model included all ACS NSQIP variables independently predictive of the outcome through forward stepwise regression, then the procedure variables
included through forward stepwise regression, then gender forced as the last independent variable.
ASA, American Society of Anesthesiologists; BMI, body mass index; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CNS, central
nervous system; DNR, do not resuscitate; SIRS, systemic inflammatory response syndrome.
aComposite morbidity was one or more of 21 adverse events uniformly defined by the ACS NSQIP.
bInfectious complications included deep, superficial or organ/space surgical site infection, pneumonia, sepsis or septic shock, and/or urinary tract infection.
cWound occurrence included deep, superficial or organ/space surgical site infection, and/or wound dehiscence.
dPulmonary complication included ventilation 48 h unplanned intubation and/or postoperative pneumonia.
eGraft/prosthesis failure was defined as, “mechanical failure of an extracardiac graft or prosthesis . . . requiring return to the operating room, interventional
radiology, or a balloon angioplasty.”
*Highlights P values 0.05.
